ITeos Therapeutics Inc Aktie News

NEW YORK , Aug. 20, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc. (NASDAQ: ITOS)'s  sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire ...

NEW YORK and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iTeos Therapeutics, Inc. (NasdaqGM: ITOS) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of iTeos will receive $10.047 in cash per share, plu...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of iTeos Therapeutics, Inc. (NasdaqGM: ITOS) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of iTeos will receive $10.047 in cash per share, plus one non-tran...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK , July 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors concerning the proposed acquisition of the company by Concentra Biosciences, LLC. Stockholders will receive $10.047 and one contingent value right for each share of iTeos Therapeutics stock that they hold.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos shareholders. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to rece...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share (“iTeos Common Stock”), plus one non-transferable cont...

- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceu...